Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Nanda

Showing results (141-150 of 144) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 144 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapyL Du, C Yau, L Brown-Swigart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2022
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trialsM Marczyk, A Mrukwa, C Yau, et al.
Clinical Pharmacology and Therapeutics|April 12, 2017
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug PrescribingP H O'Donnell, N Wadhwa, K Danahey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancerA C Garrido-Castro, S E Kim, T Li, et al.
Pageof 15

Showing results (141-150 of 144) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 144 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapyL Du, C Yau, L Brown-Swigart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2022
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trialsM Marczyk, A Mrukwa, C Yau, et al.
Clinical Pharmacology and Therapeutics|April 12, 2017
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug PrescribingP H O'Donnell, N Wadhwa, K Danahey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancerA C Garrido-Castro, S E Kim, T Li, et al.
Pageof 15